Sales of Biogen Idec's Tysabri curbed by PML cases
This article was originally published in Scrip
Executive Summary
Biogen Idechas reduced its sales growth projections for its multiple sclerosis drug Tysabri (natalizumab), following another case of progressive multifocal leucoencephalopathy (PML) in a patient who had been receiving the drug – the fifth case reported in the past 12 months.